Personalized Whole-Pelvis Hypofractionated Radiotherapy with Prostate Dose Escalation and Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer A Phase II Single-Arm Study
Led by German Oncology Center, Cyprus · Updated on 2026-09-17
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a new approach to personalize radiation therapy for men with high-risk localized prostate cancer using multimodal artificial intelligence MMAI. This phase II study evaluates a combination of treatments including prostate dose escalation with high-dose-rate HDR brachytherapy, two years of androgen deprivation therapy ADT, and ultra-hypofractionated whole-pelvis radiotherapy UHF-RT. The goal is to assess treatment safety and cancer control outcomes in this specific patient group.
All participants will receive a standardized treatment regimen involving a single fraction of HDR brachytherapy delivering 15 Gy to the prostate, followed by ultra-hypofractionated external beam radiotherapy to the elective pelvic lymph nodes at 25 Gy over five fractions. Alongside radiation, patients will undergo two years of ADT using luteinizing hormone-releasing hormone agonists or antagonists. The radiation techniques include intensity-modulated and image-guided radiotherapy. This study lasts about three weeks for radiation delivery, with ADT continuing for 24 months.
Participants will be monitored closely for side effects and cancer progression over a minimum of five years. Regular assessments will include toxicity evaluations, survival measures, quality of life questionnaires, and blood tests including testosterone levels. Researchers will also analyze MMAI-based risk predictions and seek biomarkers to improve treatment personalization. Follow-up visits are scheduled frequently during and after treatment to track outcomes and safety.
CONDITIONS
Brief Title
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
Research Team
E
Elena Pallari, PhD
K
Kristis Vevis, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Primary high- or very high-risk prostate cancer by NCCN criteria
Age over 18 years
Signed informed consent
Prior PSMA-PET/CT, mpMRI, or PSMA-PET/MR imaging
MMAI high-risk classification
ECOG performance score 0 or 1
IPSS score 15 or less
You will not qualify if you...
Prior radiotherapy to prostate or pelvis
Prior radical prostatectomy
Prior focal prostate therapy
Pelvic nodal disease or distant metastases on imaging
More than 2 months between start of systemic therapy and PSMA-PET scans
cT4 disease on imaging
PSA over 50 ng/ml before systemic therapy
Expected survival less than 5 years
Bilateral hip prostheses or implants causing CT artifacts
Contraindications to MRI or HDR brachytherapy
Significant prostate surgery or recent TURP/HOLEP within 6 months
Medical conditions making radiotherapy inadvisable
Recent malignancy within 2 years except skin cancers
Contraindications to pelvic EBRT
Participation in other interventional trials within 30 days
Legal incapacity to consent
Known substance abuse
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Approximately 3 weeks for radiotherapy; 24 months for hormone therapy
Participants receive prostate HDR brachytherapy, ultra-hypofractionated whole-pelvis radiotherapy, and two years of androgen deprivation therapy.
Six radiation treatment fractions over 3 weeks; ongoing hormone therapy visits
Follow-up
Duration - Minimum 5 years
Participants are monitored regularly for side effects, cancer progression, and quality of life for at least five years.
Multiple follow-up visits scheduled throughout the 5-year period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors